论文部分内容阅读
为了解丹参酮的抗癌作用并探索其机理，用丹参酮处理人肝癌细胞株和白血病细胞株，Ｂｒｄｕ掺入标记和ＰＣＮＡ免疫组化染色检测癌细胞增殖动力学指标。结果：丹参酮处理人肝癌细胞和白血病细胞株后，Ｂｒｄｕ标记率分别为８．９５％，１９．０１％，均显著低于对照组（２８．０％，２５．５７％，Ｐ＜０．０１）；ＰＣＮＡ阳性率分别为５７．０％，３０．３２％，均显著低于对照组（７４．３％，４７．０５％，Ｐ＜０．０１）。结果表明，Ｂｒｄｕ标记和ＰＣＮＡ检测在研究肿瘤细胞增殖及影响因素等方面有重要应用价值，丹参酮抑制癌细胞增殖与抑制癌细胞ＤＮＡ合成、ＰＣＮＡ表达及ＤＮＡ多聚酶δ活性等有关。
To understand the anticancer effect of tanshinone and explore its mechanism, tanshinone was used to treat human hepatocellular carcinoma cell lines and leukemia cell lines, Brdu incorporation marker and PCNA immunohistochemistry to detect the proliferation kinetic parameters of cancer cells. Results: After tanshinone treatment of human hepatoma cells and leukemia cell lines, Brdu labeling rates were 8.95% and 19.01%, respectively, which were significantly lower than the control group (28.0%, 25.57%, P<0.01). The positive rates of PCNA were 57.0% and 30.32%, respectively, which were significantly lower than those of the control group (74.3%, 47.05%, P<0.01). The results showed that Brdu labeling and PCNA detection have important application value in the study of tumor cell proliferation and influencing factors. Tanshinone inhibited cancer cell proliferation and inhibited cancer cell DNA synthesis, PCNA expression and DNA polymerase δ activity.